Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/198205
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorSantos-Lozano, J. M.es_ES
dc.contributor.authorRada, Mirellaes_ES
dc.contributor.authorLapetra, Josées_ES
dc.contributor.authorGuinda Garín, M. Ángeleses_ES
dc.contributor.authorJiménez-Rodríguez, María C.es_ES
dc.contributor.authorCayuela, José Antonioes_ES
dc.contributor.authorÁngel-Lugo, Antonioes_ES
dc.contributor.authorVilches-Arenas, Ángeles_ES
dc.contributor.authorGómez-Martín, Ana M.es_ES
dc.contributor.authorOrtega-Calvo, Manueles_ES
dc.contributor.authorCastellano, José Maríaes_ES
dc.date.accessioned2020-01-17T11:26:49Z-
dc.date.available2020-01-17T11:26:49Z-
dc.date.issued2019-11-
dc.identifier.citationDiabetes, Obesity and Metabolism. A Journal of Pharmacology and Therapeutics 21 (11): 2526-2534 (2019)es_ES
dc.identifier.issn1462-8902-
dc.identifier.urihttp://hdl.handle.net/10261/198205-
dc.description26 Páginas.-- 3 Tablas.-- 2 Figurases_ES
dc.description.abstractAim To assess whether the regular intake of an oleanolic acid (OA)‐enriched olive oil is effective in the prevention of diabetes. Methods In the PREDIABOLE study, prediabetic individuals (impaired fasting glucose and impaired glucose tolerance) of both sexes (176 patients, aged 30‐80 years) were randomized to receive 55 mL/day of OA‐enriched olive oil (equivalent dose 30 mg OA/day) [intervention group (IG)] or the same oil not enriched [control group (CG)]. The main outcome was the incidence of new‐onset type 2 diabetes in both groups. Results Forty‐eight new diabetes cases occurred, 31 in the CG and 17 in the IG. The multivariate‐adjusted hazard ratio was 0.45 (95% CI, 0.24‐0.83) for the IG compared with the CG. Intervention‐related adverse effects were not reported. Conclusions The intake of OA‐enriched olive oil reduces the risk of developing diabetes in prediabetic patients. The results of the PREDIABOLE study promote the use of OA in new functional foods and drugs for the prevention of diabetes in individuals at risk of developing it.es_ES
dc.description.sponsorshipThe authors especially thank the ACESUR Group (Dos Hermanas, Seville, Spain), which donated all the commercial olive oil for the trial. This collaborator had no role in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication. The authors also express their gratitude to Dr. Alberto Gil‐Peralta, Neurology Service of the Virgen del Rocío University Hospital (Seville, Spain), for the critical reading of the manuscript and his helpful comments. CIBEROBN is an initiative of Instituto de Salud Carlos III (ISCIII), Madrid, Spain. The PREDIABOLE study was supported by the official funding agency for biomedical research of the Spanish Government, ISCIII, through the Fondo de Investigación para la Salud (FIS), which is co‐funded by the European Regional Development Fund, including the following projects: PI10/00913 (led by J.M.S.‐L.) and PI10/01415 (led by J.A.C.). The study was also supported by a grant of Consejería de Salud de la Junta de Andalucía (PI‐0037/2008, led by J.M.S.‐L.). None of the funding sources took part in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication.es_ES
dc.language.isoenges_ES
dc.publisherJohn Wiley & Sonses_ES
dc.relation.isversionofPostprintes_ES
dc.rightsopenAccessen_EN
dc.subjectantidiabetic druges_ES
dc.subjectOleanolic acides_ES
dc.subjectphase I‐II studyes_ES
dc.subjectprimary carees_ES
dc.subjectrandomized triales_ES
dc.subjectrandomized trial type 2 diabeteses_ES
dc.titlePrevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled triales_ES
dc.typeartículoes_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1111/dom.13838es_ES
dc.identifier.e-issn1463-1326-
dc.embargo.terms2020-11-01es_ES
dc.contributor.funderJunta de Andalucíaes_ES
dc.contributor.funderEuropean Commissiones_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100011011es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.openairetypeartículo-
item.fulltextWith Fulltext-
item.languageiso639-1en-
Aparece en las colecciones: (IG) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
PostP_2019_DOM_V21_P2526.pdfArtículo principal514,14 kBAdobe PDFVista previa
Visualizar/Abrir
Supp_Mat.pdf229,77 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

Page view(s)

183
checked on 27-abr-2024

Download(s)

523
checked on 27-abr-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.